Taldefgrobep alfa
BHV-2000 · BHV2000-202 · Biohaven
A myostatin/activin-pathway inhibitor being studied for weight reduction and body composition.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Body-composition and other targets appear alongside hormone pathways in this overview.
Explore the hormone anatomy ↗Obesity stage by formulation
Latest: Biohaven reported on October 29, 2026, that the Phase 2 obesity study remains ongoing and is being amended to assess combination treatment with a GLP-1-based therapy.
Next: Sponsor expects monotherapy and combination topline results in the second half of 2027; the combination amendment remains in progress.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
REV-OBESITY · BHV2000-202
Weight managementPhase 2 study in overweight adults and adults with obesity. Biohaven’s October 29 update describes a GLP-1 combination amendment in progress and H2 2027 topline timing; no obesity efficacy result was disclosed.
